As prescription drug costs remain high, states are establishing Prescription Drug Affordability Boards (PDABs) to control prices, but these boards face challenges, including legal action, as seen with Colorado's PDAB. The boards aim to make drugs more affordable through cost reviews and setting upper payment limits, although their decisions are often contested by drug manufacturers. Click here for article.
PDAB Initiatives: Eleven states have established or are considering Prescription Drug Affordability Boards (PDABs) to address high drug prices, with Maryland and Colorado leading the way.
Colorado's Legal Challenge: Colorado’s PDAB is facing a lawsuit from drug manufacturer Amgen over its decision to set upper payment limits on drugs like Enbrel, with claims that this decision is unconstitutional and conflicts with federal patent law.
Drug Cost Reviews: Maryland’s PDAB is reviewing costs of drugs like Ozempic and Trulicity, considering setting upper payment limits to control prices for state and local governments.
Minnesota's Focus: Minnesota is setting up its PDAB to target high-cost drug families and understand the complex supply chain contributing to elevated drug prices.
Yorumlar